It took close to three years, but Germany's Evotec AG has finally reached its first big milestone in a biomarker collaboration first signed with Switzerland drug and diagnostic giant Roche back in 2011.
French diagnostics giant bioMérieux closed its $450 million acquisition of Utah's BioFire Diagnostics only in January, but the investment is already beginning to pay off.
MDxHealth will ally with a Texas-based provider network in a deal that will greatly expand the reach of its signature prostate cancer molecular diagnostic test to millions of additional patients.
KineMed, a California biomarker test developer with IPO plans, is joining a consortium that will create a standard mouse model focused on diagnosis and tracking of early-onset diabetes.
A rapid diagnostic blood test for asthma--one that works even in mild cases, before symptoms appear--showed some promise in new research. What's more, the handheld device developed for the diagnostic process would cost little to use, they said.
Cepheid booked much higher sales during its fiscal 2014 first quarter and successfully launched new HPV and norovirus molecular diagnostic tests outside of the U.S. But the California company faced a net loss as it dealt with higher overall costs and continued to work through restructuring.
Investors drove Abbott Laboratories' stock higher the week before Easter, heartened by diagnostics sales that keep climbing even as its medical devices arm faced continued challenges.
Eventus Diagnostics in Miami raised a $2.72 million investment infusion that it will use to advance its Octava breast cancer diagnostic blood tests.
ERBA Diagnostics has something to crow about for 2013. Year-over-year, the Florida in vitro diagnostics outfit swung from a net loss to a small profit, aided, in part, by a surge in new revenue stemming from a 2012 acquisition. The company said it is eyeing more M&A deals in 2014.
Sequenom scored against Illumina's Verinata Health in a ruling at the U.S. Patent and Trademark Office involving noninvasive prenatal genetic diagnostic tech. Wasting no time, executives plan to use that decision as a weapon in an ongoing legal battle between the two California companies.
Despite heavy competition, GE Healthcare will forge ahead with its ongoing acquisition spree, division chairman and CEO John Dineen has said. Execs are continuing their search for more information technology and life sciences diagnostic deals to help enhance the company's edge.
Qiagen snatched up a biomarker from an Austrian research group that will aid in the development of a test designed to better diagnose rare blood disorders.
The University of California and a Chinese company will launch a high-end medical lab in Shanghai expected to handle molecular diagnostics and other tests for Chinese patients. They're billing the initiative as the first of its kind between a Chinese company and a U.S. academic medical center.
Philips Healthcare is touting some positive early results from a field study of its new hand-held blood test to spot patients at high risk for heart attacks or other "acute cardiac events."
Merck's venture capital arm is the lead investor in a $12 million financing round for promising molecular diagnostic outfit AdvanDx. Their target: hospital-acquired infections that are increasingly producing drug-resistant strains.
Exact Sciences President and CEO Kevin Conroy previously promised that 2014 will be all about getting the company's Cologuard colon cancer test to market. Now, the company will be armed with close to $120 million to get the job done.
We all know that med tech venture funding declined in 2013 in an ongoing trend in which those numbers have fallen for years. But we've seen some signs of VC life, and yes, even optimism, in 2014. Among the optimists: Barcelona venture capital firm Ysios Capital.
Seattle's Adaptive Biotechnologies has pulled in $105 million from Viking Global Investors to finish off combined Series C and D rounds. The cash infusion will expand the commercial reach of the company's immunosequencing tech to help diagnose and treat cancer, infectious diseases and autoimmune disorders.
Another newly discovered biomarker is now under consideration as a tool to help evaluate and treat disease. When the body expresses it, it appears to be tied to better survival chances in both non-small cell lung cancer and head and neck cancer.
Roche's Ventana Medical Systems will work with Denmark's Genmab to come up with a companion diagnostic test to be paired with a targeted anticancer drug now in development.